GHRH receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-22. Anything still debated is marked as such rather than presented as settled.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Appearance as powder | White to off-white solid | Minor batch-to-batch variation is normal |
| Solubility class | Soluble in water and aqueous buffers | Dissolution can be slowed by aggregates |
| Typical storage temperature | Minus 20 degrees Celsius or below | Protected from light and moisture |
| Storage after reconstitution | 2 to 8 degrees Celsius, short term | Longer holding requires freezing |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity and identity confirmation |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
The concept was successful enough to become a permanent fixture of the chain, and Little Caesars' business model has shifted to focus more on carryout. In 1998, Little Caesars filled what was then the largest pizza order, filling an order of 13,386 pizzas from the VF Corporation of Greensboro, North Carolina. Little Caesars was among the first to use a new kind of speed-cooking conveyor oven, the "Rotary Air Impingement Oven". On December 10, 2014, Little Caesars announced plans for a new eight-story, 205,000-square-foot Global Resource Center to be built at Woodward Avenue and Columbia Street in downtown Detroit. Intended to double the size of Little Caesars World Headquarters Campus, the new building's location was chosen near the Fox Office Center building, which houses both the Fox Theatre, and 186,000 square feet of office space for Little Caesars, and other Ilitch-affiliated ventures. An overhead pedestrian bridge over Columbia Street was planned to connect the Fox with the new Little Caesars Global Resource Center and workspace for an additional 600 jobs to be brought to Detroit over time. On January 31, 2016, it was announced that the proposed new Little Caesars Pizza Global Resource Center had grown by one floor to be a nine-story building at Woodward and Columbia Street. The building was scheduled to be completed in 2018, but in October of that year, was pushed back due to construction delays.
=== Jonathan Monk === Jonathan Michael Monk (born February 2, 1987), originally from North Carolina, was born to an 18-year-old mother and 24-year-old father. From the beginning, Monk’s home life was marked by instability and abuse. According to testimony, his mother was abused by his father, and after their eventual divorce, Monk's father left the family. Following the separation, Monk’s mother, who was neglectful towards Monk and his siblings, frequently moved the family and had a series of boyfriends, at least one of whom was consistently abusive toward Monk, his mother, and his siblings. Despite the emotional instability, Monk experienced a brief period of emotional stability during his time in Terlingua, Texas, where a former teacher described him as becoming part of her family. He showed talent in gymnastics and formed close friendships that brought some normalcy to his youth. Monk joined the U.S. Army at the age of 17, due to his family members previously serving in the military. He served two deployments in Afghanistan, where he experienced combat-related trauma. During his second deployment, he faced personal crises including a second divorce caused by his wife’s infidelity and disciplinary action for violating military alcohol rules. His brother and others described a noticeable change in his behavior upon his return, marked by heavy drinking, poor sleep, and erratic behavior. In 2011, Monk was convicted of attempted first degree murder for a brutal knife attack on Tabatha Dupree, the wife of a fellow soldier and friend named Justin Dupree.
Washing and sorting food source Juice extraction Straining, filtration and clarification Blending pasteurization Filling, sealing and sterilization Cooling, labeling and packing After the fruits are picked and washed, the juice is extracted by one of two automated methods. In the first method, two metal cups with sharp metal tubes on the bottom cup come together, removing the peel and forcing the flesh of the fruit through the metal tube. The juice of the fruit then escapes through small holes in the tube. The peels can then be used further, and are washed to remove oils, which are reclaimed later for usage. The second method requires the fruits to be cut in half before being subjected to reamers, which extract the juice. After the juice is filtered, it may be concentrated in evaporators, which reduce the size of the juice by a factor of 5, making it easier to transport and increasing its expiration date. Juices are concentrated by heating under a vacuum to remove water, and then cooling to around 13 degrees Celsius. About two-thirds of the water in a juice is removed. The juice is later reconstituted, a process in which the concentrate is mixed with water and other factors to restore any lost flavor from the concentrating process. Juices can also be sold in a concentrated state, in which the consumer adds water to the concentrated juice as preparation. Juices are then pasteurized and filled into containers, often while still hot. If the juice is poured into a container while hot, it is cooled as quickly as possible.
Taylor Farms recalls all iceberg lettuce sourced from central Mexico after federal health officials link shredded lettuce supplied by the company and served at Taco Bell restaurants in five states to an outbreak of cyclosporiasis that infects at least 1,644 people and hospitalizes 94. July 18 2026 Iran war: Iranian Deputy Foreign Minister Kazem Gharibabadi states that Iran suspended implementation of MoU commitments as part of the interim deal with the US, accusing the latter of breaching its own obligations. CENTCOM states that two American soldiers were killed, one went missing, four others were injured and some others were slightly wounded while defending against Iranian ballistic missile and drone attacks in Jordan the day before. On the same day, CENTCOM states that the US struck Iranian targets including Iranian troops who attacked its soldiers in retaliation to IRGC attack on its service members in Jordan. Social media personalities Andrew and Tristan Tate are arrested by the U.S. Marshals Service in Miami following a British request for their extradition. The brothers face charges in the United Kingdom including rape, assault and human trafficking, while Andrew also faces offences relating to indecent images of a child and extreme pornography. Both deny the allegations. July 19 2026 Iran war: U.S. forces shoot down Iranian missiles above Aqaba. The U.S.
The album was met with moderate commercial success and favorable reviews. Review aggregating website Metacritic reports a normalized score of 71% based on 7 reviews. Entertainment Weekly wrote that "the silky-voiced folk-popster successfully rocks up his sound on his fourth album, adding a polite but firm electric edge".
Sources: en.wikipedia.org
Enterochromaffin-like cells or ECL cells are a type of neuroendocrine cell found in the gastric glands of the gastric mucosa beneath the epithelium, in particular in the vicinity of parietal cells, that aid in the production of gastric acid via the release of histamine. They are also considered a type of enteroendocrine cell.
==== Bevacizumab ==== Through binding to VEGFR and other VEGF receptors in endothelial cells, VEGF can trigger multiple cellular responses like promoting cell survival, preventing apoptosis, and remodeling cytoskeleton, all of which promote angiogenesis. Bevacizumab (brand name Avastin) traps VEGF in the blood, lowering the binding of VEGF to its receptors. This results in reduced activation of the angiogenesis pathway, thus inhibiting new blood vessel formation in tumors. After a series of clinical trials in 2004, Avastin was approved by the FDA, becoming the first commercially available anti-angiogenesis drug. FDA approval of Avastin for breast cancer treatment was later revoked on November 18, 2011.
== Coaching == In 1993, the Milwaukee Brewers named Epstein manager of the rookie league Helena Brewers, who played in the Pioneer League. He only managed 11 games, as his hitting philosophy learned under Ted Williams was contrary to the current trend at the time.
=== Pharmacodynamics === KNX-100 produces oxytocin-like effects, such as pro-social, anti-aggressive, and anti-addictive effects among others, in rodents and monkeys. The drug reduced self-administration of methamphetamine in rats by 85%, of cocaine in rhesus monkeys by 90%, and of alcohol in baboons by more than 50%. It is thought that KNX-100 may produce its antiaddictive effects by discounting drug reward in favor of social reward. In addition to its antiaddictive effects, KNX-100 reduces opioid withdrawal and nicotine withdrawal symptoms in animals. It appears to act to reduce opioid withdrawal symptoms by suppressing increased dynorphin/κ-opioid receptor signaling in the nucleus accumbens shell. Unexpectedly, KNX-100 did not show affinity for the oxytocin receptor nor act as an agonist, antagonist, or positive allosteric modulator of the receptor, but nonetheless robustly activates oxytocinergic signaling. In fact, KNX-100 can activate oxytocinergic signaling and cause associated effects to a greater extent than oxytocin itself. Screening at more than 100 different receptors and transporters was initially unable to identify the drug's biological target. It was suggested that KNX-100 may be acting at an upstream target to indirectly modulate the oxytocin system and increase oxytocin production. Subsequently, KNX-100 was said by its developers to have a novel undisclosed mechanism of action.
Sources: en.wikipedia.org
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.
Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.
Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.